IonQ, Inc. (NYSE: IONQ) officer Dacier Paul T forfeited 4,457 shares at $37.09 per share on Sep 11, 2026. He serves as the company’s CAO, CLO and Secretary. The transaction involved an existing IonQ share position held by the executive. The transaction date was …
Intuitive Surgical (NASDAQ:ISRG) sells expensive robotic systems that help surgeons operate, but the real engine of itsBusinessis not the machines themselves: it is the number of procedures performed on them. Because the company earnsRecurring Revenueevery time a surgeon uses one of its robots, procedure …
Munro Douglas received 2,882 shares of Mercury Systems (NASDAQ: MRCY) in an award. The filing reported the resulting ownership after the transaction.
● Nano-X Imaging posted 37%Revenuegrowth alongside aGAAPnet loss of $55.5 million driven by a $40.7 millionImpairmentcharge.
OMNIQ Corp. (OTC: OMQS) received U.S. Patent No. 12,633,155 for an AI system that detects vehicle occupancy in moving traffic, extending its technology into HOV lane enforcement.
Regeneron (NASDAQ:REGN) has built a formidableBusinesson a handful of blockbuster medicines, but its future depends on what comes next. As its older products face growing competition, pipeline progress, turning laboratory science into approved, saleable drugs, is crucial to itsNasdaq100 healthcare story.
SANGRIX INC. (NASDAQ: SGRX) is repositioning its public identity around AI computing infrastructure with a new corporate website, logo and investor-relations contact.
● Synergy CHC disclosed aNasdaqnotice on 20 August 2026 for failing to timely file its Form 10-Q for the quarter ended 30 June 2026, with a compliance plan due by 19 October 2026.
Vertex Pharmaceuticals (NASDAQ:VRTX) built a remarkableBusinessby dominating the treatment of a single rare disease, cystic fibrosis. Now the crucial question forNasdaq100 investors is whether it can repeat that success elsewhere, because itsLong-term Growthdepends on expanding beyond theFranchisethat made it, into new areas such as …
D.R. Horton, Inc. (NYSE: DHI) added $5.0 billion to its authorization for common-stock repurchases on September 15. The board-approved authorization has no expiration date.